title: Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg).
abstract: Transplantation of patients possessing antibodies against allo-HLA antigens can be delayed for years. We have shown that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti-HLA antibodies. We report here the first series of patients desensitized, then transplanted using IVIg therapy. Fifteen patients have been included and treated with IVIg, given as 3 monthly courses of 2g/kg body weight. Thirteen of those 15 patients (87%) were effectively desensitized and underwent immediate transplantation. Eleven were transplanted with a cadaveric donor, and two with a living donor against which the pretreatment cross-match was positive. One graft was lost from thrombosis and one from rejection. All other patients had uneventful courses, without any episodes of rejection, with a follow-up of more than 1 year. Thus, IVIg therapy allows safe and prompt kidney transplantation of immunized patients.
authors.affiliation: Department of Nephrology, INSERM U 430, Hĵpital Européen Georges Pompidou, Paris, France. denis.glotz@egp.ap-hop-paris.fr
authors.forename: Denis
authors.initials: D
authors.lastname: Glotz
authors.forename: Corinne
authors.initials: C
authors.lastname: Antoine
authors.forename: Pierre
authors.initials: P
authors.lastname: Julia
authors.forename: Caroline
authors.initials: C
authors.lastname: Suberbielle-Boissel
authors.forename: Samir
authors.initials: S
authors.lastname: Boudjeltia
authors.forename: Rabah
authors.initials: R
authors.lastname: Fraoui
authors.forename: Chafic
authors.initials: C
authors.lastname: Hacen
authors.forename: Alain
authors.initials: A
authors.lastname: Duboust
authors.forename: Jean
authors.initials: J
authors.lastname: Bariety
mesh_terms: D000293:Adolescent; D000328:Adult; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000494:pharmacology* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous